Leerink lowered the firm’s price target on McKesson to $665 from $670 and keeps an Outperform rating on the shares. After McKesson management appeared at a competitor conference this morning and provided additional details on the full year cadence, the firm is lowering its FY25 EPS estimate to $32.05 from $32.25, but maintains its FY26 EPS estimate of $36.03. The cadence for the course of the year makes the ramping of growth, especially for Med-Surg, and to a lesser extent RxTS, “more challenging,” but the selloff since earnings provides “a much more appealing entry point,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson selling Rexall and Well.ca businesses to Birch Hill Equity Partners
- Boeing’s Starliner to return without astronauts: Morning Buzz
- McKesson Expands Influence with Core Ventures Acquisition
- McKesson to acquire controlling interest in Core Ventures for $2.49B in cash
- McKesson in talks to buy Florida Cancer Specialists for $3.5B, Bloomberg says